Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.
Controlled study in people · 1987
- What was studied
- Patients with chronic insomnia; double-blind crossover
- Main finding
- A double-blind crossover study found little clinically significant sleep improvement with DSIP; some nominal sleep-stage differences were already present at baseline.
Reported findings and study design
A double-blind crossover study found little clinically significant sleep improvement with DSIP; some nominal sleep-stage differences were already present at baseline.
Insomnia patients studied over four nights with polysomnography; sample size not stated in the abstract.
Population or model Patients with chronic insomnia; double-blind crossover
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Awakenings and wake time | Decreased during DSIP, without significant baseline or placebo differences | Also applies to NREM latency and waking after sleep onset |
| NREM and stage 2 sleep | Nominal differences versus placebo, with the same differences already present at baseline | |
| Slow-wave and REM sleep | Not modified | |
| Studied exposure | 25 nmol/kg intravenously; four-night crossover |
The abstract contains no sleep-duration effect sizes or arm-level counts. Its conclusion is limited clinical significance.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- Baseline differences complicate interpretation; sample size is not provided in the indexed abstract.
Source details
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Sources checked
Citation
Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. International journal of clinical pharmacology research 7(2):105-110